Windlas Biotech

Windlas Biotech Equity

The The Equity of Windlas Biotech (WINDLAS.NS) as of Oct 18, 2026 is 5.81 B INR. In the previous year, The Equity was 5.06 B INR — a change of 14.84% (higher).

Equity

5.81 BINR

YoY

14.84%

Last updated:

In 2026, Windlas Biotech's equity was 5.81 B INR, a 14.84% increase from the 5.06 B INR equity in the previous year.

The Windlas Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
1.94 B INR
Jan 1, 2020
2.10 B INR
Jan 1, 2021
1.99 B INR
Jan 1, 2022
3.95 B INR
Jan 1, 2023
4.02 B INR
Jan 1, 2024
4.50 B INR
Jan 1, 2025
5.06 B INR
Jan 1, 2026
5.81 B INR
The Windlas Biotech Equity history
YEAREquityYoY
5.81 BINR+14.84%
5.06 BINR+12.41%
4.50 BINR+11.85%
4.02 BINR+1.90%
3.95 BINR+98.26%
1.99 BINR-5.03%
2.10 BINR+8.30%
1.94 BINR+54.82%
1.25 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Windlas Biotech Stock analysis

What does Windlas Biotech do? Windlas Biotech Ltd is a contract development and manufacturing organization based in Dehradun, Uttarakhand, India. Listed on the National Stock Exchange with ticker WINDLAS.NS, the company employs 1,049 full-time staff. It provides comprehensive CDMO services, including product discovery, development, licensing, and commercial manufacturing of generic products, with a focus on complex generics. The firm specializes in therapeutic areas such as anti-diabetic, cardiovascular, neuropsychiatry, and respiratory treatments. Its capabilities cover formulation development, technology scale-up, and full-scale commercial manufacturing for both solid and liquid pharmaceutical dosage forms. Beyond contract services, Windlas markets its own nutraceutical, pharmaceutical, and Ayurvedic products to semi-urban and rural communities through a salesforce and distribution network spanning over 14 states. The company conducted its initial public offering on August 16, 2021. Windlas Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Windlas Biotech's Equity

Windlas Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Windlas Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Windlas Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Windlas Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Windlas Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Windlas Biotech stock

The Equity of Windlas Biotech is 5.81 B INR in 2026.

The Equity of Windlas Biotech changed from 5.06 B INR to 5.81 B INR, representing a 14.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Windlas Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Windlas Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Windlas Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Windlas Biotech